.svg.png){kind=small}
.svg){kind=small}
Science-based cannabis company has the first cannabis cultivation and extraction license in Germany
XPhyto is a science-based cannabis company focusing on medical formulation, clinical validation, and emerging European markets. Further, the company was created to take advantage of the next wave of investment opportunity in the cannabis industry.
Moreover, XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices.
"We believe the German market will be the largest medical market in the world for both medical products and consumer products...", says CEO and Director, Hugh Rogers.
About XPhyto Therapeutics
XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, importing, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.
For more information on XPhyto Therapeutics Corp. (XPHY:CSE) please fill out the form below.
.png){kind=small}
